收藏切换
Evaluating the current status of the application of sacubitril valsartan in hypertensive patients based on clinical pharmacy intelligent prescription review system
收藏切换
Ning WANG, Yingyun GUAN, Xiaolan BIAN*
World Clinical Drug | 2023, 44(1) : 94 - 100
Less
收藏切换
World Clinical Drug | 2023, 44(1): 94-100
• Pharmacy administration •
Evaluating the current status of the application of sacubitril valsartan in hypertensive patients based on clinical pharmacy intelligent prescription review system
Full
Ning WANG, Yingyun GUAN, Xiaolan BIAN*
Affiliations
  • Department of Pharmacy, Ruijin Hospital, Shanghai JiaoTong University, School of Medicine, Shanghai 200025, China
Published: 2023-01-10 doi: 10.13683/j.wph.2023.01.016
Outline
收藏切换
Objecitve

To understand the current status of the application of sacubitril valsartan in hypertensive patients in China and evaluate its rationality in clinical application.

Methods

Through the prescription review system of the clinical pharmacy intelligent platform, all outpatient prescriptions with hypertension diagnosed and Sacubitril Valsartan used during the period from June 1 2021 to June 30 2022 were extracted, and the collected data were statistically and analyzed.

Results

A total of 17 100 qualified prescriptions were extracted. The top three departments in the number of prescriptions were hypertension department, cardiology department and nephrology department. Hypertension combined diseases were mainly cardiac insufficiency and renal insufficiency. Through the initial system screen and manual review, 1 033 unreasonable prescriptions were found, accounting for 6.04% of the total number of prescriptions. The main unreasonable problems were repeated drugs and the unreasonable use of combined drugs.

Conclusion

The population of application of Sacubitril Valsartan in hypertensive patients is increasing day by day, but the rationality of medication needs to be further improved. Pharmacists should strengthen the publicity and education of rational medication for doctors and patients to ensure the safety and effectiveness of new antihypertensive drugs in clinical application.

sacubitril valsartan  /  hypertension  /  rational drug use  /  intelligent prescription review system
王宁, 管滢芸, 卞晓岚. 基于临床药学智慧平台处方点评系统评价沙库巴曲缬沙坦在高血压患者中的应用现状. 世界临床药物, 2023 , 44 (1) : 94 -100 . DOI: 10.13683/j.wph.2023.01.016
Ning WANG, Yingyun GUAN, Xiaolan BIAN. Evaluating the current status of the application of sacubitril valsartan in hypertensive patients based on clinical pharmacy intelligent prescription review system[J]. World Clinical Drug, 2023 , 44 (1) : 94 -100 . DOI: 10.13683/j.wph.2023.01.016
Year 2023 volume 44 Issue 1
9
2
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2023.01.016
  • Receive Date:2022-08-17
  • Online Date:2026-11-18
  • Published:2023-01-10
Article Data
Affiliations
History
  • Received:2022-08-17
Funding
Affiliations
    Department of Pharmacy, Ruijin Hospital, Shanghai JiaoTong University, School of Medicine, Shanghai 200025, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2023.01.016
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT